TY - CHAP
T1 - Modeling Human Liver Steatosis in Induced Pluripotent Stem Cell-Derived Liver Spheres
AU - Kasarinaite, Alvile
AU - Hay, David C
N1 - © 2025. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2025/5/1
Y1 - 2025/5/1
N2 - Alterations in cellular metabolism are a major contributor to the worldwide obesity crisis. Numerous defects underpin this disease, and a major contributor is the development of metabolic dysfunction associated with steatotic liver disease (MASLD). This can lead to the progressive form of liver disease termed Metabolic Dysfunction Associated Steatohepatitis (MASH) and this can lead to end-stage liver disease (Wong VWS, Adams LA, de Ledinghen V et al, Nat Rev Gastroenterol Hepatol 8:461-478, 2018). While liver transplantation is highly successful at treating end-stage liver disease, it is severely limited by organ donation and limited by the requirement for life-long immunosuppression. Therefore, to better understand the disease, and identify new biomarkers, and therapeutics for MASLD/MASH, new human cell-based models are required (Wong VWS, Adams LA, de Ledinghen V et al, Nat Rev Gastroenterol Hepatol 8:461-478, 2018). Therefore, we have developed a scalable liver tissue engineering platform from induced pluripotent stem cells (iPSCs) to study human liver metabolic disease in vitro.
AB - Alterations in cellular metabolism are a major contributor to the worldwide obesity crisis. Numerous defects underpin this disease, and a major contributor is the development of metabolic dysfunction associated with steatotic liver disease (MASLD). This can lead to the progressive form of liver disease termed Metabolic Dysfunction Associated Steatohepatitis (MASH) and this can lead to end-stage liver disease (Wong VWS, Adams LA, de Ledinghen V et al, Nat Rev Gastroenterol Hepatol 8:461-478, 2018). While liver transplantation is highly successful at treating end-stage liver disease, it is severely limited by organ donation and limited by the requirement for life-long immunosuppression. Therefore, to better understand the disease, and identify new biomarkers, and therapeutics for MASLD/MASH, new human cell-based models are required (Wong VWS, Adams LA, de Ledinghen V et al, Nat Rev Gastroenterol Hepatol 8:461-478, 2018). Therefore, we have developed a scalable liver tissue engineering platform from induced pluripotent stem cells (iPSCs) to study human liver metabolic disease in vitro.
KW - Humans
KW - Induced Pluripotent Stem Cells/cytology
KW - Fatty Liver/pathology
KW - Liver/pathology
KW - Tissue Engineering/methods
KW - Spheroids, Cellular/metabolism
KW - Cell Differentiation
KW - Models, Biological
KW - Cell Culture Techniques/methods
KW - Hepatocytes/metabolism
U2 - 10.1007/978-1-0716-4530-7_11
DO - 10.1007/978-1-0716-4530-7_11
M3 - Chapter (peer-reviewed)
C2 - 40307641
SN - 9781071645291
SN - 9781071645321
VL - 2924
T3 - Methods in molecular biology (Clifton, N.J.)
SP - 145
EP - 161
BT - Cell-Based Assays Using iPSCs for Drug Development and Testing
A2 - Mandenius, Carl-Fredrik
A2 - Ross, James A.
CY - New York, NY
ER -